Eneapharm is delighted to take part in this leading international event, bringing together industry leaders, experts, and decision makers.

A key gathering to share the latest advancements, strengthen collaborations, and shape the solutions of tomorrow.
On this occasion, we will have the honor of presenting:

– EN311, our innovative oral formulation designed to address the major challenges in treating exocrine pancreatic insufficiency (EPI) in adults.

– EN3103, our new nasogastric formulation in development, specifically designed for a group of patients who currently have no adapted therapeutic option.

We look forward to engaging with our target market, decision makers, and strategic partners around these high-impact innovations.

Karim Ioualalen,CEO & Rosanne Raynal,COO look forward to meeting you and exploring new perspectives and their decisive role in the future of EPI treatment.